Predicting relapse in schizophrenia: Is BDNF a plausible biological marker?

Area of Science:

• Neuroscience
• Psychiatry
• Biomarker Research

Background:

• Schizophrenia relapse is a significant clinical challenge.
• Brain Derived Neurotrophic Factor (BDNF) is implicated in brain plasticity and is reduced in schizophrenia.
• Identifying reliable biomarkers for relapse prediction is crucial.

Purpose of the Study:

• To investigate if plasma Brain Derived Neurotrophic Factor (BDNF) levels can serve as a biological predictor of relapse in schizophrenia.
• To evaluate the association between baseline BDNF levels and adverse outcomes like relapse, hospitalization, or exacerbation.

Main Methods:

• Prospective evaluation of 221 schizophrenia patients over 30 months in the PROACTIVE study.
• Serial plasma samples collected up to 23 time points.
• BDNF levels measured by ELISA; analyzed using Receiver Operating Characteristic (ROC) curve analysis.

Main Results:

• Plasma BDNF levels were not found to be a significant predictor of relapse, hospitalization, or exacerbation.
• No significant difference in baseline BDNF levels between patients who experienced adverse outcomes and those who did not.
• Results were consistent across different treatment groups (oral antipsychotics vs. long-acting injectables).

Conclusions:

• Plasma BDNF alone is not a suitable biomarker for predicting relapse in schizophrenia.
• Further research may be needed to explore other potential biomarkers or combinations of factors.
• These findings contribute to understanding the biological underpinnings of schizophrenia relapse.